Does dioxin exert toxic effects in humans at or near current background body levels?: An evidence-based conclusion

Human and Experimental Toxicology

Volumn 25, Issue 2, 2006, Pages 99-105

  Guzelian, P ^a   Quattrochi, L ^a   Karch, N ^b   Aylward, L ^b   Kaley, R ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE   (United States)

Author keywords

Cytochrome P450 IA2; Dioxin; Evidence based toxicology

Indexed keywords

CYTOCHROME P450 1A2; DIOXIN;

ARTICLE; AUTHORITY; BODY BURDEN; ENVIRONMENTAL PROTECTION; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; EVIDENCE BASED TOXICOLOGY; HUMAN; NONHUMAN; PRIORITY JOURNAL; SCIENCE; TOXICOKINETICS; TOXICOLOGY;

BODY BURDEN; DIOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL POLLUTANTS; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 33644780910     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327106ht594oa     Document Type: Article

References (43)

1. Guzelian PS, Victoroff M, Halmes NC, James RC, Guzelian CP. Evidence-based toxicology: a comprehensive framework for causation. Hum Exp Toxicol 2005; 24: 161-201.
2. Guzelian PS, Guzelian CP. Authority-based explanation. Science 2004; 303: 1468-69.
3. Aylward LL, Lamb JC, Lewis SC. Issues in risk assessment for developmental effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Toxicol Sci 2005; 87: 3-10.
4. Gaylor DW, Aylward LL. An evaluation of benchmark dose methodology for non-cancer continuous-data health effects in animals due to exposures to dioxin (TCDD). Regul Toxicol Pharmacol 2004; 40: 9-17.
5. Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S. Human CYP1A2 sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol Endocrinol 1989; 3: 1399-408.
6. Williams SN, Pickwell GV, Quattrochi LC. A combination of tea (Camellia senensis) catechins is required for optimal inhibition of induced CYP1A expression by green tea extract. J Agric Food Chem 2003; 51: 6627-23.
7. Xu L, Li AP, Kaminski DL, Ruh MF. 2,3,7,8 Tetrachlorodibenzo-p-dioxin induction of cytochrome P4501A in cultured rat and human hepatocytes. Chem Biol Interact 2000; 124: 173-89.
8. Nemoto N, Sakurai J. Activation of cyp1a1 and cyp1a2 genes in adult mouse hepatocytes in primary culture. Jpn J Cancer Res 1993; 84: 272-78.
9. Denison MS, Whitlock JP Jr. Xenobiotic-inducible transcription of cytochrome P450 genes. J Biol Chem 1995; 270: 18175-78.
10. Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SST, Kimura S et al. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 1995; 268: 722-26.
11. Schmidt JV, Su GH-T, Reddy JK, Simon MC, Bradfield CA. Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci USA 1996; 93: 6731-36.
12. Quattrochi LC, Vu T, Tukey RH. The human CYP1A2 gene and induction by 3-methylcholanthrene: a region of DNA that supports Ah-receptor binding and promoter-specific induction. J Biol Chem 1994; 269: 6949-54.
13. Black VH, Quattrochi LC. Molecular cloning of the guinea pig CYP1A2 gene 5′-flanking region: identification of functional AHRE and characterization of CYP1A2 expression in GPC16 cells. Drug Metab Dispos 2004; 32: 595-602.
14. Sogawa K, Numayama-Tsuruta K, Takahashi T, Matsushita N, Miura C, Nikawa J et al. A novel induction mechanism of the rat CYP1A2 gene mediated by Ah receptor-Arnt heterodimer. Biochem Biophys Res Commun 2004; 318: 746-55.
15. Le Marchand L, Franke AA, Custer L, Wilkens LR, Cooney RV. Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and alpha-tocopherol. Pharmacogenetics 1997; 7: 11-19.
16. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999; 125: 803.
17. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Therapeut 2004; 76: 178-84.
18. Rost KL, Brosicke H, Brockmoller J, Scheffler M, Helge H, Roots I. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Therapeut 1992; 52: 170-80.
19. Sinha R, Rothman N, Brown ED, Mark SD, Hoover RN, Caporaso NE et al. Panfried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans. Cancer Res 1994; 54: 6154-59.
20. Kall MA, Vang O, Clausen J. Effects of dietary broccoli on human in vivo drug metabolizing enzymes: evaluation of caffeine, oestrone and chlorzoxazone metabolism. Carcinogenesis 1996; 17: 793-99.
21. Derkenne S, Curran CP, Shertzer HG, Dalton TP, Nadine Dragin N, Nebert DW. Theophylline pharmacokinetics: comparison of Cyp1a1(-/-) and Cyp1a2(-/-) knockout mice, humanized hCYP1A1_1A2 knock-in mice lacking either the mouse Cyp1a1 or Cyp1a2 gene, and Cyp1(+/+) wild-type mice. Pharmacogen Genom 2005; 15: 503-11.
22. Halperin W et al. Induction of P-450 in workers exposed to dioxin. Occup Environ Med 1995; 52: 86 91.
23. Abraham K, Geusau A, Yalcin T, Helge H, Steffen Bauer S, Brockmöller J. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction. Clin Pharmacol Therapeut 2002; 72: 163-74.
24. Lambert GH, Hsu CC, Guo L, Ryan JJ, Schoeller DA. The dose response relationship between the serum levels of polychlorinated biphenyls (PCBs) and polychlorinated dibenzofurans (PCDFs) and cytochrome P4501A2 activity as determined by the caffeine breath test. Organohal Comp 1994; 21: 485-88.
25. Connor KT, Aylward LL. Human response to dioxin: aryl hydrocarbon receptor (AhR) molecular structure, function, and dose-response data for enzyme induction indicate an impaired human AhR. J Toxicol Environ Health Crit Rev Part B (in press).
26. Ayotte P, Dewailly E, Lambert Perkins SL, Poon R, Feeley M, Larochelle C et al. Biomarker measurements in a coastal fish-eating population environmentally exposed to organochlorines. Environmental Health Perspectives. Retrieved 1 June 2005, from http://dx.doi.org/ doi:10.1289/ehp.7970
27. Lambert GH, Mocarelli P, Hsu CC, Needham LL, Ryan JJ, Guo L et al. Cytochrome P4501A2 activity in dioxin exposed Seveso subjects as compared topolychlorinated biphenyl and polychorinated dibenzofuran exposed yucheng subjects. Organohal Comp 1993; 14: 253-56.
28. DeRose K. Contextualism and knowledge attributions. Philos Phenomenal Res 1992; 52: 913-29.
29. Staskal DF, Diliberto JJ, DeVito MJ, Birnbaum LS. Inhibition of human and rat CYP1A2 by TCDD and dioxin-like chemicals. Toxicol Sci 2005; 84: 225-31.
30. Chen JJ, Chen GS, Bunce NJ. Inhibition of CYP 1A2-dependent MROD activity in rat liver microsomes: an explanation of the hepatic sequestration of a limited subset of halogenated aromatic hydrocarbons. Environ Toxicol 2003; 18: 115-19.
31. Popper KR. The logic of scientific discovery. Routledge, 1980.
32. Andrew G, Smith BC, Robinson S, Scullion MJ, Carthew P, Edwards R et al. Interaction between iron metabolism and 2,3,7,8-tetrachlorodibenzo-p-dioxin in mice with variants of the Ahr gene: a hepatic oxidative mechanism. Mol Pharmacol 1998; 53: 52-61.
33. Hanioka N, Jinno HT, Ando M. The effect of 1,2,3,4-tetrachlorodibenzo-p- dioxin on drug-metabolizing enzymes in the rat liver. Chemosphere 1994; 29: 2477-91.
34. Drahushuk AT, McGarrigle BP, Tai HL, Kitareewan S, Goldstein JA, Olson JR. Validation of precision-cut liver slices in dynamic organ culture as an in vitro model for studying CYP1A1 and CYP1A2 induction. Toxicol Appl Pharmacol 1996; 140: 393-403.
35. Uno S, Dalton TP, Sinclair PR, Gorman N, Wang B, Smith AG et al. Cyp1a1(-/-) male mice: protection against high-dose TCDD-induced lethality and wasting syndrome, and resistance to intrahepatocyte lipid accumulation and uroporphyria. Toxicol Appl Pharmacol 2004; 196: 410-21.
36. Leung HW, Wendung JM, Orth R, Hileman F, Paustenbach DJ. Relative distribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin in human hepatic and adipose tissues. Toxicol Letts 1990; 50: 275-82.
37. Muller GF, Dohr O, El-Bahay C, Kahl R, Abel J. Effect of transforming growth factor-beta1 on cytochrome P450 expression: inhibition of CYP1 mRNA and protein expression in primary rat hepatocytes. Arch Toxicol 2000; 74: 145-52.
38. Pichard-Garcia L, Weaver RJ, Eckett N, Scarfe G, Fabre JM, Lucas C et al. The olivacine derivative S 16020 (9-hydroxy-5,6-dimethyl-N-[2-(dimethylamino) ethyl)-6h-pyrido(4,3-B)-carbazole-1-carboxamide) induces cyp1a and its own metabolism in human hepatocytes in primary culture. Drug Metab Dispos 2004; 32: 80-88.
39. Sun YV, Boverhof DR, Burgoon LD, Fielden MR, Zacharewski TR. Comparative analysis of dioxin response elements in human, mouse and rat genomic sequences. Nucl Acids Res 2004; 32: 4512-23.
40. Lucier GW, Nelson KG, Everson RB, Wong TK, Philpot RM, Tiernan T et al. Placental markers of human exposure to polychlorinated biphenyls and polychlorinated dibenzofurans. Environ Health Perspect 1987; 76: 79-87.
41. Schecter A, Startin J, Wright C, Papke Ball O, Lis MA. Concentrations of polychlorinated dibenzo-p-dioxins and dibenzofurans in human placental and fetal tissues from the U.S. and in placentas from Yu-Cheng exposed mothers. Chemosphere 1996; 32: 551-57.
42. Pereg D, Dewailly E, Poirier GG, Ayotte P. Environmental exposure to polychlorinated biphenyls and placental CYP1A1 activity in Inuit women from northern Quebec. Environ Health Perspect 2002; 110: 607-12.
43. Ayotte P, Dewailly Ryan E, Bruneau S, Lebel G. PCBs and dioxin-like compounds in plasma of adult Inuit living in Nunavik (Arctic Quebec). Chemosphere 1997; 34: 1459-68.